

Ozempic Lawsuits Expose Negligence in Failure to Warn Patients of Serious Side Effects

ZeroRisk Cases is providing signed cases in lawsuits against the suppliers of Ozempic, a drug commonly used to treat type 2 diabetes.

ALLENTOWN, PENNSYLVANIA, US, December 11, 2023 / EINPresswire.com/ -- ZeroRisk Cases a



ZeroRisk Cases Client Acquisition Agency

leading mass tort and personal injury client acquisition agency, is providing signed cases in lawsuits against the suppliers of Ozempic, a drug commonly used to treat type 2 diabetes. These claims allege that the drug can cause severe gastrointestinal issues such as gastroparesis, ileus, and digestive tract blockage. Plaintiffs argue that the suppliers were negligent in not warning patients about these potential side effects.



...we are dedicated to helping law firms grow their Ozempic litigation practice." Ed Lott, Ph.D., M.B.A. The first lawsuit was filed on August 2, 2023 (Bjorklund v. Novo Nordisk A/S et al Case Number: 2:2023cv01020). As of November 2023, there have been no class action suits or Multidistrict Lawsuits (MDL) cases related to Ozempic. This highlights the importance of individual representation

for those affected by this medication.

According to the lawsuits against Ozempic's manufacturer Novo Nordisk, since its approval by the FDA in 2017, there have been no warnings included regarding gastroparesis in its prescription information. The company has cautioned about other adverse effects but failed to inform the public about the risk of severe gastroparesis.

Addressing this issue head-on with their signature approach to securing higher settlement awards for law firms, is ZeroRisk Cases' President and Managing Partner Ed Lott: "We understand how important it is for individuals who have experienced serious side effects from medications like Ozempic to seek justice," said Lott. "Through our comprehensive lead-generation campaigns and targeted advertising efforts across various platforms including TV, radio, and social media channels such as Facebook and Instagram and using organic SEO

strategies, we are dedicated to helping law firms grow their Ozempic litigation practice."

ZeroRisk Cases utilizes cutting-edge tactics such as mobile marketing through Voice Search technology to effectively capture high-quality leads within specific target demographics. Additionally, the agency employs remarketing and behavioral targeting techniques to present tailored messages at opportune moments, resulting in valuable phone conversions. "Our goal is simple," continued Lott. "We want to maximize victims' success in securing the compensation they deserve by working with the top litigation firms."

For more information about ZeroRisk Cases, Inc. and their innovative strategies for law firms looking to grow their Ozempic litigation practice, visit http://www.zeroriskcases.com and http://www.zerorisktorts.com.

About ZeroRisk Cases

ZeroRisk Cases, Inc. is a reputable mass tort and personal injury client acquisition agency specializing in attracting high-quality litigants for law firms. The company launches practical and effective lead-generation campaigns that deliver measurable results. Their ZeroRisk Compliance Program™ is designed to reduce or eliminate lead fraud and fake leads that are becoming more prevalent in today's legal market.

For more information about ZeroRisk Cases, Inc. and their game-changing approach to securing higher settlement awards for law firms, visit their websites at https://www.zeroriskcases.com and https://www.zerorisktorts.com.

Ed Lott
ZeroRisk Cases, Inc.
+1 484-222-8330
edl@zeroriskcases.com
Visit us on social media:
Facebook
Twitter
LinkedIn

YouTube

This press release can be viewed online at: https://www.einpresswire.com/article/672323755

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.